Immunomodulatory effects of Interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with Ziv-aflibercept

被引：0
|
作者：
Khunger, Arjun [1 ]
Sarikonda, Ghanashyam [2 ]
Frankel, Paul [3 ]
Tsau, Jenn [2 ]
Alfonso, Zeni [2 ]
Gao, Jane [2 ]
Pahuja, Anil [2 ]
Vaupel, Christine [2 ]
Dakappagari, Naveen [2 ]
Tangri, Shabnam [2 ]
Tarhini, Ahmad [4 ,5 ]
机构：
[1] Mem Hosp West, Pembroke Pines, FL USA
[2] Navigate BioPharma Serv Inc, Carlsbad, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Winship Comprehens Canc Ctr, Atlanta, GA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P13
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
    Joanna Baginska
    Allison Nau
    Ilana Gomez Diaz
    Anita Giobbie-Hurder
    Jason Weirather
    Juliana Vergara
    Charlotte Abrecht
    Margaret Hallisey
    Jenna Dennis
    Mariano Severgnini
    Julia Huezo
    Isabella Marciello
    Osama Rahma
    Michael Manos
    Andrew S. Brohl
    Philippe L. Bedard
    Daniel J. Renouf
    Elad Sharon
    Howard Streicher
    Patrick A. Ott
    Elizabeth I. Buchbinder
    F. Stephen Hodi
    Cancer Immunology, Immunotherapy, 2024, 73
  • [2] Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
    Baginska, Joanna
    Nau, Allison
    Gomez Diaz, Ilana
    Giobbie-Hurder, Anita
    Weirather, Jason
    Vergara, Juliana
    Abrecht, Charlotte
    Hallisey, Margaret
    Dennis, Jenna
    Severgnini, Mariano
    Huezo, Julia
    Marciello, Isabella
    Rahma, Osama
    Manos, Michael
    Brohl, Andrew S.
    Bedard, Philippe L.
    Renouf, Daniel J.
    Sharon, Elad
    Streicher, Howard
    Ott, Patrick A.
    Buchbinder, Elizabeth I.
    Hodi, F. Stephen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (01)
  • [3] NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
    Tarhini, Ahmad A.
    Frankel, Paul
    Ruel, Christopher
    Ernstoff, Marc S.
    Kuzel, Timothy M.
    Logan, Theodore F.
    Khushalani, Nikhil I.
    Tawbi, Hussein A.
    Margolin, Kim A.
    Awasthi, Sanjay
    Butterfield, Lisa H.
    McDermott, David
    Chen, Alice
    Lara, Primo N.
    Kirkwood, John M.
    CANCER, 2018, 124 (22) : 4332 - 4341
  • [4] NCI 8628-A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma
    Tarhini, Ahmad A.
    Frankel, Paul H.
    Ruel, Christopher
    Ernstoff, Marc S.
    Kuzel, Timothy M.
    Logan, Theodore F.
    Khushalani, Nikhil I.
    Tawbi, Hussein A.
    Margolin, Kim A.
    Awasthi, Sanjay
    McDermott, David F.
    Chen, Alice
    Lara, Primo N.
    Kirkwood, John M.
    CANCER RESEARCH, 2017, 77
  • [5] Budgetary impact of adding ziv-aflibercept to a United States health plan formulary as a post-oxaliplatin biologic option for patients with metastatic colorectal cancer (mCRC).
    Huff, Keith
    Drea, Edward
    Hennessy, Daniel
    Thompson, Stephen F.
    Dhawan, Ravinder
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy
    Olencki, T
    Finke, J
    Tubbs, R
    Tuason, L
    Greene, T
    McLain, D
    Swanson, SJ
    Herzog, P
    Stanley, T
    Edinger, M
    Budd, GT
    Bukowski, RM
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (01) : 69 - 80
  • [7] NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma-Efficacy and biomarker study
    Ashraf, Madeeha
    Kirkwood, John M.
    Ernstoff, Marc S.
    Abdul-Hassan, Hussein Tawbl
    Frankel, Paul Henry
    Ruel, Nora
    Kendra, Karl Lynn
    Olencki, Thomas
    Khushalani, NIkhil I.
    Logan, Theodore F.
    Margolin, Kim Allyson
    Chen, Alice P.
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer
    Bendell, Johanna C.
    Thompson, Dana
    Hemphill, Brian M.
    Wenk, David
    Earwood, Chris
    Lane, Cassie M.
    Kennedy, Andrew
    CANCER INVESTIGATION, 2017, 35 (08) : 535 - 540
  • [9] Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients pretreated with bevacizumab.
    Sobrero, Alberto F.
    Bordonaro, Roberto
    Bencardino, Katia
    Pietrantonio, Filippo
    Bauer, Stefan
    Taieb, Julien
    Garreau-Laporte, Pascale
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Lledo, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients age 65 and older.
    Bordonaro, Roberto
    Frassineti, Luca
    Ciuffreda, Libero
    Aprile, Giuseppe
    Thomas, Anne L.
    Vishwanath, Raghu
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Taieb, Julien
    Sobrero, Alberto F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345